The prevalence of gestational diabetes is increasing in Australia. Non-pharmacological intervention with dietary measures and exercise is the mainstay of therapy in most cases, but insulin is increasingly necessary to achieve adequate glycaemic control in some women. Basal-bolus insulin is the optimal management strategy, but therapy needs to be individualised. Although there is mounting evidence for the efficacy and safety of metformin, the lack of long-term follow-up data has prevented it from being recommended by most experts in the field. women with gestational diabetes need long-term follow-up because of their increased risk of type 2 diabetes.
Introduction
Gestational diabetes is defined as an intolerance to glucose that is first diagnosed or has its onset during pregnancy. It is estimated to affect almost 5% of pregnancies in Australia and between 3% and 9% worldwide. Its prevalence increases with age, from 1% in women aged 15-19 years to 13% in those aged 44-49 years. 1 Other risk factors for developing gestational diabetes include being overweight or obese, having a family history of type 2 diabetes or a personal or family history of gestational diabetes or glucose intolerance, being from an Aboriginal or Torres Strait Islander background or belonging to certain ethnic groups (for example Polynesian, Middle Eastern, Indian or other Asian origin). 2 Although gestational diabetes does not affect perinatal mortality, it does increase morbidity, including the risk of shoulder dystocia, nerve palsies and neonatal hypoglycaemia. Maternal outcomes are also affected, with a higher incidence of pre-eclampsia and caesarean section (particularly with poor glycaemic control) in mothers who develop gestational diabetes. 3 
Diagnosis
Universal screening for gestational diabetes has been recommended in Australia since 1998. A fasting glucose challenge test should be performed at 26-28 weeks gestation. If abnormal, this is followed by a formal two-hour 75 g oral glucose tolerance test. Criteria for diagnosis are presented in Table 1 . For women at risk of gestational diabetes, a glucose tolerance test can be performed at any stage during pregnancy. However, as placental production of diabetogenic hormones tends to increase throughout the second and third trimesters, a normal glucose tolerance test in the early part of pregnancy does not exclude the development of gestational diabetes later on. A second oral glucose tolerance test should therefore be performed at the standard 26-28 weeks of gestation even if an earlier test was normal.
New recommendations for screening and diagnosis are currently under consideration, but have yet to be adopted or approved by expert groups in gestational diabetes. It is likely, however, that the glucose challenge test will be removed from the screening process, so that a diagnosis of gestational diabetes will be made if the blood glucose is abnormal when fasting, or one or two hours after a 75 g glucose load (see Table 1 ).
Blood glucose targets
Once diagnosed, all women need to be educated about the possible implications of gestational diabetes (both fetal and maternal) and be taught how to perform home blood glucose monitoring. Finger-prick testing should be performed four times any one of three:
a day (before breakfast and two hours after each meal). Target blood glucose concentrations, shown in Table 2 , need to be explained.
The results of the Hyperglycemia and Adverse Pregnancy
Outcomes trial have demonstrated that the risks associated with maternal hyperglycaemia are on a continuum above the normal blood glucose concentration and treatment targets might be lowered in the future to reflect this. 4 As yet, a consensus on where these targets will be set has not been established.
Non-pharmacological interventions
All women with gestational diabetes should receive advice from a dietitian with specific knowledge in the area and dietary Insulin therapy needs to be individualised and is dependent upon the patient's blood glucose concentrations, her weight and her wishes. The regimen is determined by whether the blood glucose is elevated when fasting, after a meal, or both.
Elevated fasting glucose
If the fasting glucose is elevated, but postprandial levels are within the recommended target range, a single bedtime injection of It remains unclear if maternal hypoglycaemia adversely affects the fetus. If there are concerns, it tends to be in women with pre-existing diabetes in the first trimester of pregnancy (during organogenesis) 7 and not in those with gestational diabetes.
Insulin doses may be anticipated to rise throughout the third trimester as a result of increasing maternal insulin resistance.
This tends to reach a plateau at 36-38 weeks.
Insulin analogues
There is currently little evidence to support the use of other insulin analogues (for example insulin glargine, insulin detemir)
in pregnancy, although their use is increasing.
Metformin
There is increasing evidence for the use of metformin in 
Sulfonylureas
Glibenclamide has the most evidence for use in pregnancy.
Unlike the older sulfonylureas, glibenclamide does not appear to cross the placenta to a significant degree. There does not appear to be an increase in fetal complications, but, like metformin, it is currently not recommended for widespread use in pregnancy because of a lack of long-term follow-up of children exposed to glibenclamide in utero.
There is little evidence for the safety or efficacy of other sulfonylureas in pregnancy and their use is not recommended.
Other drugs
There are few data about the safety or efficacy of acarbose, thiazolidinediones or incretin mimetics and enhancers in pregnancy. Currently these drugs are not recommended and their use in pregnancy should be considered experimental.
Follow-up and prognosis
Gestational diabetes resolves postpartum in more than 90% of women. In general, all insulin and oral hypoglycaemic drugs are ceased immediately postpartum with ongoing blood glucose monitoring until discharge from hospital. If concentrations return to normal, which occurs in the overwhelming majority of cases, a repeat glucose tolerance test should be performed 6-8 weeks postpartum to ensure that the patient does not have overt type 2 diabetes.
The long-term risk for developing type 2 diabetes is increased over sevenfold in women who develop gestational diabetes compared with those who have a normoglycaemic pregnancy. 9 Women with a pre-pregnancy BMI of more than 27 kg/m 2 , those of advancing maternal age and those who required insulin for glycaemic control in pregnancy are at particularly increased risk. 10 It is important to counsel women about these issues and is not necessary to prescribe the stated maximum quantity as PBS prescriptions and repeats can be for any amount up to the maximum quantity.
